One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Scholar Rock Holding Corporation logo
Scholar Rock Holding Corporation SRRK
$ 46.77 3.31%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Scholar Rock Holding Corporation Cash Flow 2025-2011 | SRRK

Brief cash flow overview of Scholar Rock Holding Corporation

The review uses the five latest available annual reports between 2021 and 2025.

Operating cash flow ended negative at -$300 million. Core operations are not yet producing a sustainable inflow.

Only 0 of five observations were above zero. The business relies heavily on individual strong periods.

Cash flow takeaway

Scholar Rock Holding Corporation's cash profile looks stretched: weak operating cash flow limits investment, payouts and debt-servicing capacity.

Annual Cash Flow Scholar Rock Holding Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-300 M -201 M -145 M -133 M -127 M -60.3 M -63.1 M 24.6 M -21.7 M - - - - - -

Depreciation & Amortization

1.66 M 1.94 M 2.84 M 2.99 M 2.63 M 1.49 M 1.3 M 807 K 669 K - - - - - -

Accounts Payables

10.3 M 10.1 M 3.46 M 3.99 M 4.43 M 3.41 M 1.13 M 3.3 M - - - - - - -

Accounts Receivables

- - - - - - 25 M - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Scholar Rock Holding Corporation

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-152 M -82.1 M - - -78.7 M - - - -49.8 M - - - -43.1 M - -104 M -77.3 M -42.6 M - -94.3 M -58.4 M -26.5 M - -40.6 M -17.2 M 2.64 M - -47 M -31.9 M -15.5 M - -30.5 M -21.5 M -9.88 M - -15.7 M -9.93 M - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

632 K 335 K - - 393 K - - - 598 K - - - 733 K - 2.24 M 1.49 M 749 K - 1.9 M 1.23 M 590 K - 1.17 M 784 K 391 K - 917 K 586 K 271 K - 567 K 359 K 179 K - 497 K 330 K - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

11 M 9.22 M 6.76 M 1.1 M 4.44 M 10.1 M 4.07 M 3.32 M 2.87 M 3.46 M 1.97 M 3.04 M 3.72 M 3.99 M 2 M 2.85 M 2.99 M 4.43 M 2.04 M 1.63 M 2.2 M 3.41 M 3.41 M 3.41 M 3.41 M 1.13 M 1.13 M 1.13 M 1.13 M 3.3 M 3.3 M 3.3 M 3.3 M 1.36 M 1.36 M 1.36 M - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Receivables

- - - - - - - - - - - - - - - - - - - - - - - - - 25 M 25 M 25 M 25 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Scholar Rock Holding Corporation, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 53.74 -3.26 % $ 6.45 M usaUSA
Prothena Corporation plc Prothena Corporation plc
PRTA
$ 7.93 0.51 % $ 427 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 10.54 7.55 % $ 1.47 B franceFrance
Rocket Pharmaceuticals Rocket Pharmaceuticals
RCKT
$ 2.38 -2.05 % $ 264 M usaUSA
Regeneron Pharmaceuticals Regeneron Pharmaceuticals
REGN
$ 904.69 0.2 % $ 94.6 B usaUSA
Replimune Group Replimune Group
REPL
$ 21.67 8.24 % $ 2.01 B usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 9.47 4.76 % $ 445 M usaUSA
Royalty Pharma plc Royalty Pharma plc
RPRX
$ 67.31 -0.39 % $ 28.9 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Rhythm Pharmaceuticals Rhythm Pharmaceuticals
RYTM
$ 111.51 6.18 % $ 7.25 B usaUSA
Puma Biotechnology Puma Biotechnology
PBYI
$ 8.28 -15.25 % $ 414 M usaUSA
SIGA Technologies SIGA Technologies
SIGA
$ 3.12 4.55 % $ 223 M usaUSA
Sage Therapeutics Sage Therapeutics
SAGE
- - $ 527 M usaUSA
Taro Pharmaceutical Industries Ltd. Taro Pharmaceutical Industries Ltd.
TARO
- - $ 1.62 B israelIsrael
Sol-Gel Technologies Ltd. Sol-Gel Technologies Ltd.
SLGL
$ 61.62 -2.21 % $ 172 M israelIsrael
SELLAS Life Sciences Group SELLAS Life Sciences Group
SLS
$ 8.41 6.73 % $ 917 M usaUSA
Summit Therapeutics Summit Therapeutics
SMMT
$ 16.34 15.15 % $ 12.2 B britainBritain
Cabaletta Bio Cabaletta Bio
CABA
$ 1.3 1.17 % $ 131 M usaUSA
Syndax Pharmaceuticals Syndax Pharmaceuticals
SNDX
$ 9.53 1.39 % $ 826 M usaUSA
Sanofi Sanofi
SNY
$ 47.06 0.32 % $ 57.4 B franceFrance
Forma Therapeutics Holdings Forma Therapeutics Holdings
FMTX
- - $ 958 M usaUSA
Blueprint Medicines Corporation Blueprint Medicines Corporation
BPMC
- - $ 8.14 B usaUSA
Horizon Therapeutics Public Limited Company Horizon Therapeutics Public Limited Company
HZNP
- - $ 26.6 B irlandaIrlanda
Sarepta Therapeutics Sarepta Therapeutics
SRPT
$ 17.8 0.68 % $ 1.78 B usaUSA
Paratek Pharmaceuticals Paratek Pharmaceuticals
PRTK
- - $ 121 M usaUSA
China SXT Pharmaceuticals China SXT Pharmaceuticals
SXTC
$ 2.84 -3.07 % $ 1.93 M chinaChina
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
$ 21.02 -0.92 % $ 33.2 B japanJapan
Tarsus Pharmaceuticals Tarsus Pharmaceuticals
TARS
$ 68.11 0.87 % $ 2.85 B usaUSA
ASLAN Pharmaceuticals Limited ASLAN Pharmaceuticals Limited
ASLN
- -14.27 % $ 1.7 M singaporeSingapore
Bio-Techne Corporation Bio-Techne Corporation
TECH
$ 72.78 0.17 % $ 11.4 B usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
$ 42.32 1.33 % $ 48.5 B israelIsrael
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.43 0.45 % $ 5.3 B israelIsrael
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Unity Biotechnology Unity Biotechnology
UBX
- -33.41 % $ 3.37 M usaUSA
iTeos Therapeutics iTeos Therapeutics
ITOS
- - $ 411 M usaUSA
Shattuck Labs Shattuck Labs
STTK
$ 4.59 2.78 % $ 319 M usaUSA
Seelos Therapeutics Seelos Therapeutics
SEEL
- -47.76 % $ 6.27 M usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.28 -16.14 % $ 2.2 M israelIsrael
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 2.33 9.15 % $ 99.8 M usaUSA
Trevi Therapeutics Trevi Therapeutics
TRVI
$ 14.33 11.87 % $ 1.93 B usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
$ 4.63 21.05 % $ 20 M israelIsrael
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 9.79 4.26 % $ 280 M usaUSA
Kiromic BioPharma Kiromic BioPharma
KRBP
- 6.61 % $ 3.08 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
$ 3.92 -2.24 % $ 1.74 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
United Therapeutics Corporation United Therapeutics Corporation
UTHR
$ 562.14 -0.63 % $ 24.9 B usaUSA
Vericel Corporation Vericel Corporation
VCEL
$ 54.56 5.36 % $ 2.75 B usaUSA